Search
Regeneron Pharmaceuticals Inc
REGNAdd to Watchlist
826.640USD
-14.200-1.69%
Close 08-20 16:00（ET）
85.48BMarket Cap
19.46P/E TTM
TradingKey Chart
Intraday
1m
30m
1h
D
W
M
D
Today
-1.69%
5 Days
+2.68%
1 Month
+23.13%
6 Months
+6.31%
Year to Date
+7.51%
1 Year
+40.59%
Key Figures
831.700Open
840.490High
41.20KVolume
19.46P/E TTM
12.89P/E Dynamic
3.580Dividend TTM
0.04%Turnover Ratio
840.840Prev. Close
826.100Low
34.31MTurnover
19.37P/E Static
2.69P/B
0.43%Div Yield TTM
11.40%ROA
844.92052wk High
0.14Volume Ratio
4.41BNet Profit
103.40MShares
42.4810EPS TTM
0.26Beta
14.69%ROE
805.93052wk Low
1.71%Amplitude
86.56%Gross Margin
85.48BMarket Cap
10.99Reward/Risk
2.12%Risk Rate
Regeneron Pharmaceuticals Inc Stock (REGN) Moved Down by 10.44% on May 18: Facts Behind the Movement
• Key Phase 3 melanoma trial failed primary endpoint. • Analysts downgraded Regeneron stock and price targets. • Collaboration with Parabilis was overshadowed by trial failure.
TradingKeyMon, May 18
Regeneron Pharmaceuticals Inc Stock (REGN) Moved Down by 7.82% on Apr 29: Facts Behind the Movement
• Regeneron reported strong Q1 2026 financial results, exceeding expectations. • Eylea sales declined due to inventory and regulatory issues with syringe. • Experimental lung cancer drug combination will not advance to late-stage trials.
TradingKeyWed, Apr 29
Trump Strikes Again: Sends Warning Letter to Eli Lilly and Others, Drug Pricing Back in the Spotlight
TradingKey - On Thursday Eastern Time, U.S. President Donald Trump renewed pressure on the pharmaceutical industry by sending formal letters to several major drugmakers
TradingKeyJul 31, 2025
Regeneron Pharmaceuticals Inc's Score
-0.07vs previous score
Forecast7.69
Financial Health9.06
Technical5.06
Valuation Dimensions7.52
Institutional Confidence10.00
Risk Assessment9.09
Media Coverage
Coverage Level
40°C
Very Low
Very High
Positive+
Analyst Rating
Regeneron Pharmaceuticals Inc Technical Analysis
Technical Indicators
Buy
Summary
Buy
Moving Average
Strong buy
Financial Indicators
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
Earnings
Next reporting date
--
Reporting Period
2026Q2
Earnings / Forecast
12.62/10.26
Revenue / Forecast
4.29B/3.82B
Regeneron Pharmaceuticals Inc Profile
SectorPharmaceuticals
Ticker SymbolREGN
Number of employees15106
CountryUnited States of America
Ownership
| Shareholders | Proportion |
|---|---|
| Vanguard Capital Management, LLC | 6.46% |
| BlackRock Institutional Trust Company, N.A. | 5.27% |
| State Street Investment Management (US) | 4.52% |
| Dodge & Cox | 4.46% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 47.12% |
| Investment Advisor/Hedge Fund | 32.63% |
| Hedge Fund | 3.44% |
| Research Firm | 2.77% |
Related Instruments
-2.81%
-2.21%
-0.28%
-1.56%
-2.11%
-2.54%
-1.95%
-2.82%
-1.59%
-0.73%
-2.14%
-3.17%
-1.48%
-1.74%
-1.75%
+0.51%
-1.15%
-2.72%
-23.55%Popular Instruments
52963.600
+180.200 (+0.34%)
29374.100
+144.600 (+0.49%)
7669.000
+21.100 (+0.28%)
14778.000
+136.000 (+0.93%)
66156.000
+656.000 (+1.00%)
6445.500
+27.200 (+0.42%)
85.902
-0.220 (-0.26%)
311.300
-5.530 (-1.75%)
216.850
-0.710 (-0.33%)
4582.000
+63.320 (+1.40%)
FAQs
What is the current price of Regeneron Pharmaceuticals Inc (REGN)?
The current price of Regeneron Pharmaceuticals Inc (REGN) is 826.64.
What is the symbol of Regeneron Pharmaceuticals Inc?
The ticker symbol of Regeneron Pharmaceuticals Inc is REGN.
What is the 52-week high of Regeneron Pharmaceuticals Inc?
The 52-week high of Regeneron Pharmaceuticals Inc is 844.92.
What is the 52-week low of Regeneron Pharmaceuticals Inc?
The 52-week low of Regeneron Pharmaceuticals Inc is 805.93.
What is the market capitalization of Regeneron Pharmaceuticals Inc?
The market capitalization of Regeneron Pharmaceuticals Inc is 85.48B.
Is Regeneron Pharmaceuticals Inc (REGN) currently rated as Buy, Hold, or Sell?
According to analysts, Regeneron Pharmaceuticals Inc (REGN) has an overall rating of Buy, with a price target of 835.47.
What is the Earnings Per Share (EPS TTM) of Regeneron Pharmaceuticals Inc (REGN)?
The Earnings Per Share (EPS TTM) of Regeneron Pharmaceuticals Inc (REGN) is 42.48.